AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16871270 — intervention group
Group type: COMPARATOR
Intervention: Placebo (initial treatment)
Number of subjects: 50
Study 16871270 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil (initial treatment)
Number of subjects: 50
Study 16871270 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label sildenafil
Number of subjects: 50
Study 16338916 — intervention group
Group type: EXPERIMENTAL
Intervention: No or low risk of self-harm based on suicidal ideation assessment
Number of subjects: 761
Study 16338916 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate risk of self-harm based on suicidal ideation assessment
Number of subjects: 761
Study 16338916 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial assessment of suicidal ideation
Number of subjects: 761
Study 12015689 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (2 g iv) plus probenecid (1 g by mouth)
Number of subjects: 116
Study 12015689 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (1 g iv) plus oral placebo
Number of subjects: 116
Study 10506666 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing-hormone (CRH) 100 microg (i.v.)
Number of subjects: 18
Study 10506666 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing-hormone (CRH) with pre-treatment with dexamethasone
Number of subjects: 18
Study 10506666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7542982 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) administration (0.03 mg.kg‐1 body wt.day‐1)
Number of subjects: 9
Study 7542982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7542982 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) administration
Number of subjects: 9
Study 1955994 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 mm incision (foldable IOL)
Number of subjects: 500
Study 1955994 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.2 mm incision (PMMA IOL)
Number of subjects: 500
Study 1955994 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.0 mm incision (PMMA IOL)
Number of subjects: 500
Study 1955994 — intervention group
Group type: COMPARATOR
Intervention: Cold versus warm balanced salt solution irrigation
Number of subjects: 500
Study 1955994 — intervention group
Group type: COMPARATOR
Intervention: Scleral cautery (complete to limbus vs. posterior to Tenon's fascia)
Number of subjects: 500
Study 7083463 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bolus - 50-70 mg/m2/day over 1 h daily for 5 days (39 patients)
Number of subjects: 77
Study 7083463 — intervention group
Group type: COMPARATOR
Intervention: Infusion - 50-70 mg/m2/day as a continuous infusion for 5 days (38 patients)
Number of subjects: 77
Study 31139827 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiprofessional preventive home visits
Number of subjects: 422
Study 31139827 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 422
Study 31072414 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% O2 group (benchtop incubator)
Number of subjects: 230
Study 27831907 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback on compression rate
Number of subjects: 50
Study 27831907 — intervention group
Group type: COMPARATOR
Intervention: No visual feedback
Number of subjects: 50
Study 27831907 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback on compression force
Number of subjects: 50
Study 27831907 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback
Number of subjects: 50
Study 26254087 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) 3.8g/day for 9 months
Number of subjects: 133
Study 26254087 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (SO)
Number of subjects: 133
Study 26254087 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO)
Number of subjects: 133
Study 24134527 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal mid-pregnancy 25-hydroxyvitamin D level (mean 73.7 nmol/L)
Number of subjects: 1248
Study 21719412 — intervention group
Group type: EXPERIMENTAL
Intervention: Online personalized feedback intervention
Number of subjects: 450
Study 21719412 — intervention group
Group type: COMPARATOR
Intervention: Information-only control condition
Number of subjects: 450
Study 19428899 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A Supplementation (VAS)
Number of subjects: 0
Study 17234331 — intervention group
Group type: EXPERIMENTAL
Intervention: Obtape
Number of subjects: 190
Study 17234331 — intervention group
Group type: EXPERIMENTAL
Intervention: DUPS
Number of subjects: 190
Study 17234331 — intervention group
Group type: COMPARATOR
Intervention: TVT
Number of subjects: 190
Study 15799918 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic connector device (ACD)
Number of subjects: 0
Study 15799918 — intervention group
Group type: COMPARATOR
Intervention: Hand-sewn grafts
Number of subjects: 0
Study 15799918 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of platelet hyperreactivity, marginal graft flow, and endothelial disease
Number of subjects: 0
Study 10924781 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 EU vaccine
Number of subjects: 242
Study 10924781 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 EU vaccine
Number of subjects: 242
Study 10924781 — intervention group
Group type: COMPARATOR
Intervention: Reference vaccine
Number of subjects: 242
Study 8931413 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. (group I)
Number of subjects: 53
Study 8931413 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg t.i.d. (group II) plus amoxicillin 750 mg t.i.d. for 14 days
Number of subjects: 53
Study 8931413 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. plus amoxicillin 750 mg t.i.d. and metronidazole 500 mg t.i.d. for 14 days (group III)
Number of subjects: 53
Study 8931413 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. plus clarithromycin 500 mg t.i.d. for 14 days (group IV)
Number of subjects: 53
Study 1524686 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF/SnF2 toothpaste plus AmF/SnF2 mouthwash
Number of subjects: 44
Study 4017156 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity expressed relative to ventilation thresholds (VT1 and VT2)
Number of subjects: 16
Study 4017156 — intervention group
Group type: COMPARATOR
Intervention: Traditional expression of intensity relative to VO2max
Number of subjects: 16
Study 3597990 — intervention group
Group type: EXPERIMENTAL
Intervention: d-sotalol (1, 1.5 or 2 mg/kg body weight)
Number of subjects: 20
Study 3597990 — intervention group
Group type: EXPERIMENTAL
Intervention: d,l-sotalol (1 mg/kg)
Number of subjects: 20
Study 29693228 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NC)
Number of subjects: 13939
Study 29132404 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg FP-1201-lyo administered intravenously once daily for 6 days
Number of subjects: 300
Study 29132404 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intravenously once daily for 6 days
Number of subjects: 300
Study 29132404 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg FP-1201-lyo
Number of subjects: 300
Study 29132404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 26314817 — intervention group
Group type: EXPERIMENTAL
Intervention: Fp MDPI 800 μg (400 μg/inhalation × 2 inhalations)
Number of subjects: 18
Study 26314817 — intervention group
Group type: COMPARATOR
Intervention: Fp DPI 1000 μg (250 μg/inhalation × 4 inhalations)
Number of subjects: 18
Study 26314817 — intervention group
Group type: COMPARATOR
Intervention: Fp MDI 880 μg (220 μg/inhalation × 4 inhalations)
Number of subjects: 18
Study 22593230 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating-shift group (experimental group)
Number of subjects: 62
Study 22593230 — intervention group
Group type: COMPARATOR
Intervention: Fixed-day-shift group (control group)
Number of subjects: 62
Study 21918240 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-delivered, theory-based support for physical activity behavior change
Number of subjects: 81
Study 21918240 — intervention group
Group type: COMPARATOR
Intervention: Basic education, gym membership, and pedometer for self-monitoring (control group)
Number of subjects: 81
Study 18513638 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson
Number of subjects: 49
Study 18513638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 17154785 — intervention group
Group type: EXPERIMENTAL
Intervention: Action gaming
Number of subjects: 0
Study 17154785 — intervention group
Group type: COMPARATOR
Intervention: Nongamers
Number of subjects: 0
Study 12556736 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam
Number of subjects: 0
Study 10898419 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (1,000 IU for three months)
Number of subjects: 41
Study 10898419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 8809957 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet alloantibodies to human platelet antigens (HPA) -1, -3 and -5
Number of subjects: 59
Study 8809957 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet alloantibodies in patients with HLA-antibodies
Number of subjects: 59
Study 8809957 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of antibody prior to transfusions
Number of subjects: 59
Study 8809957 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-antibodies reacting with over 95% of unselected lymphocytes
Number of subjects: 59
Study 1331023 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 2766 (40 mg/day for 8 weeks)
Number of subjects: 20
Study 3914177 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 92
Study 3914177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 29397214 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine
Number of subjects: 199
Study 29397214 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine
Number of subjects: 199
Study 27058909 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagal nerve stimulation (VNS)
Number of subjects: 707
Study 27058909 — intervention group
Group type: COMPARATOR
Intervention: Continued medical therapy (control)
Number of subjects: 707
Study 24688260 — intervention group
Group type: EXPERIMENTAL
Intervention: ImageJ evaluation of optic disc pallor
Number of subjects: 35
Study 22986318 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) lidocaine 1.5 mg/kg 20 minutes before incision followed by a continuous lidocaine infusion of 1.5 mg/kg/hr until the end of surgery
Number of subjects: 48
Study 22986318 — intervention group
Group type: COMPARATOR
Intervention: Saline in a similar manner (control group)
Number of subjects: 48
Study 22986318 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) lidocaine
Number of subjects: 48
Study 20520820 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous application of inactivated influenza vaccine (TETAGRIP)
Number of subjects: 36
Study 20520820 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) immunization with inactivated influenza vaccine (TETAGRIP)
Number of subjects: 36
Study 18442338 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention for never smokers
Number of subjects: 2066
Study 18442338 — intervention group
Group type: COMPARATOR
Intervention: Current smokers
Number of subjects: 2066
Study 16039487 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal hinge LASIK
Number of subjects: 24
Study 16039487 — intervention group
Group type: COMPARATOR
Intervention: Superior hinge LASIK
Number of subjects: 24
Study 12455077 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (1 mg over 2 min) administered via an infusion catheter distal to the angioplasty site.
Number of subjects: 212
Study 12455077 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 patients with AMI and TIMI grade 3 flow).
Number of subjects: 212
Study 10793956 — intervention group
Group type: EXPERIMENTAL
Intervention: Realtime teledermatology
Number of subjects: 204
Study 10793956 — intervention group
Group type: COMPARATOR
Intervention: Conventional outpatient consultation
Number of subjects: 204
Study 10793956 — intervention group
Group type: EXPERIMENTAL
Intervention: Store-and-forward teledermatology
Number of subjects: 204
Study 10793956 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost analysis of realtime teledermatology
Number of subjects: 204
Study 10793956 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost analysis of store-and-forward teledermatology
Number of subjects: 204
Study 10793956 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analysis of realtime teledermatology
Number of subjects: 204
Study 8969027 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine administered intraluminally, retrograde in the internal mammary artery
Number of subjects: 106
Study 8969027 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine administered topically
Number of subjects: 106
Study 8969027 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine administered perivascularly in the pedicle
Number of subjects: 106
Study 1569444 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-cyclophosphamide (75 mg/m2 and 600 mg/m2)
Number of subjects: 447
Study 1569444 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-cyclophosphamide (300 mg/m2 and 600 mg/m2)
Number of subjects: 447
Study 1569444 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-cyclophosphamide
Number of subjects: 447
Study 1569444 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-cyclophosphamide
Number of subjects: 447
Study 3885884 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg every 6 hours for one week)
Number of subjects: 200
Study 3885884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 31112554 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI-based attention training program (3 sessions per week for 8 weeks, followed by 3 sessions per month for 12 weeks)
Number of subjects: 172
Study 31112554 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control group (received similar 20-week intervention after an 8-week wait)
Number of subjects: 172
Study 31112554 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled group (after full 20-week treatment)
Number of subjects: 172
Study 29615645 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 280
Study 29615645 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 280
Study 26949378 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein hydrolysate-carbohydrate beverage (PRO-CHO, 14 g protein/h and 69 g CHO/h)
Number of subjects: 18
Study 26949378 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric carbohydrate beverage (CHO, 84 g/h)
Number of subjects: 18
Study 25557316 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (2000 IU cholecalciferol daily)
Number of subjects: 184
Study 25557316 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (600 IU daily)
Number of subjects: 184
Study 25557316 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (1200 IU daily)
Number of subjects: 184
Study 25557316 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo) in study 2
Number of subjects: 184
Study 25557316 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo) in study 3
Number of subjects: 184
Study 24304745 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory training program
Number of subjects: 0
Study 24304745 — intervention group
Group type: COMPARATOR
Intervention: Placebo version of the working memory training program
Number of subjects: 0
Study 19351798 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (125 mg)
Number of subjects: 38
Study 19351798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 18156921 — intervention group
Group type: EXPERIMENTAL
Intervention: Division of short gastric vessels
Number of subjects: 102
Study 18156921 — intervention group
Group type: COMPARATOR
Intervention: Non-division of short gastric vessels
Number of subjects: 102
Study 15985295 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 64
Study 12973482 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin at a dose of 4 mg/kg every 24 hours (protocol group)
Number of subjects: 100
Study 12973482 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin at a dose of 2.5 mg/kg every 12 hours (control group)
Number of subjects: 100
Study 10338171 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with 1 mg morphine sulfate (MS)
Number of subjects: 79
Study 10338171 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with 3 mg MS
Number of subjects: 79
Study 10338171 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 79
Study 10338171 — intervention group
Group type: COMPARATOR
Intervention: 1 mg MS in saline
Number of subjects: 79
Study 10338171 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 79
Study 8717567 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of 0.5 mg of Syntometrine
Number of subjects: 112
Study 8717567 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 125 ug of prostaglandin 15‐methyl F2 alpha
Number of subjects: 112
Study 1828508 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple therapy (T) group, N = 33
Number of subjects: 63
Study 1828508 — intervention group
Group type: COMPARATOR
Intervention: Control (C) group, N = 30
Number of subjects: 63
Study 6116040 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical spinning-disc nebuliser
Number of subjects: 8
Study 6116040 — intervention group
Group type: COMPARATOR
Intervention: Conventional compressed air nebuliser
Number of subjects: 8
Study 30865242 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 0
Study 30865242 — intervention group
Group type: COMPARATOR
Intervention: Rested individuals
Number of subjects: 0
Study 27902833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor alone
Number of subjects: 12140
Study 27902833 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel-GPI
Number of subjects: 12140
Study 25804495 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/perindopril arginine (10/14 mg/d)
Number of subjects: 837
Study 25804495 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril erbumine (16 mg/d)
Number of subjects: 837
Study 25804495 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (10 mg/d)
Number of subjects: 837
Study 24053609 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback-controlled robotics-assisted treadmill exercise
Number of subjects: 0
Study 24053609 — intervention group
Group type: COMPARATOR
Intervention: Conventional robotics-assisted treadmill exercise
Number of subjects: 0
Study 21389626 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein hydrolysate tablets (5 times more than the effective amount)
Number of subjects: 48
Study 21389626 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 48
Study 19542034 — intervention group
Group type: EXPERIMENTAL
Intervention: Prekindergarten education group
Number of subjects: 123
Study 19542034 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study 17942268 — intervention group
Group type: EXPERIMENTAL
Intervention: Video with narrative evidence (patient anecdotes)
Number of subjects: 600
Study 17942268 — intervention group
Group type: EXPERIMENTAL
Intervention: Video with statistical evidence
Number of subjects: 600
Study 17942268 — intervention group
Group type: EXPERIMENTAL
Intervention: Video with both narrative and statistical evidence
Number of subjects: 600
Study 17942268 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no video)
Number of subjects: 600
Study 15552163 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound treatment
Number of subjects: 20
Study 15552163 — intervention group
Group type: COMPARATOR
Intervention: Contralateral control site
Number of subjects: 20
Study 11574355 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron 12.5 mg IV administered 10-15 min before induction of anesthesia
Number of subjects: 105
Study 11574355 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron 12.5 mg IV administered at the end of laparoscopy (79 +/- 48 min later than Group 1)
Number of subjects: 105
Study 11574355 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron 12.5 mg IV administered at the end of anesthesia (93 +/- 52 min later than Group 1)
Number of subjects: 105
Study 9506639 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-elemental formula without enzyme replacement
Number of subjects: 16
Study 9506639 — intervention group
Group type: COMPARATOR
Intervention: Nonelemental formula with enzyme replacement
Number of subjects: 16
Study 9506639 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulas
Number of subjects: 16
Study 8573704 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position (Group A)
Number of subjects: 82
Study 8573704 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position (Group A)
Number of subjects: 82
Study 8573704 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-lying position (Group A)
Number of subjects: 82
Study 8573704 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing position (Group A)
Number of subjects: 82
Study 8573704 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position (Group B)
Number of subjects: 82
Study 8573704 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position (Group B)
Number of subjects: 82
Study 2504794 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training programs (three cost-effective programs)
Number of subjects: 154
Study 2504794 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training program combining group discussion and video-tape modeling
Number of subjects: 154
Study 322835 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (cytosine arabinoside and 6-thioguanine administered every 12 hours until marrow cellularity reduced by at least 50%)
Number of subjects: 147